Hormonal
Semaglutide 2.4 mg weekly produces significant weight loss (approx. 14.9%) in overweight and obese adults without diabetes, significantly outperforming placebo and older GLP-1 agonists like liraglutide.
Semaglutide 2.4 mg (Wegovy) is a once-weekly injection approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Clinical trials show it can lead to an average 14.9% body weight loss over 68 weeks when combined with diet and exercise. This is significantly more effective than older GLP-1 drugs like liraglutide. Common side effects include nausea and diarrhea, which are usually mild and decrease over time.
Semaglutide 2.4 mg once weekly was associated with a significant weight reduction (-14.9% in the semaglutide group compared with -2.4% in the placebo group) during 68 weeks in overweight and obese participants without diabetes [135].
Why this rating
Based on large-scale, randomized, double-blind, placebo-controlled clinical trials (STEP 1).
Source
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Eun Roh et al. · International Journal of Molecular Sciences · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →